Treatment of MGN A roundtable discussion based on best evidence Drs Cattran Expert Panel Dr Ruggenenti,Falk,Ponticelli,Fervenza,Remuzzi
|
|
- Anthony Chapman
- 6 years ago
- Views:
Transcription
1 Treatment of MGN A roundtable discussion based on best evidence Drs Cattran Expert Panel Dr Ruggenenti,Falk,Ponticelli,Fervenza,Remuzzi
2 Level Definition of evidence Randomized, controlled trial (RCT) that demonstrated a statistically significant difference in at least one important outcome OR If the difference is not statistically significant, an RCT of adequate sample size to exclude a 25% difference in relative risk with 80% power, given the observed results RCT that does not meet level 1 criteria Non-randomized trial with contemporaneous controls selected by some systematic method (i.e. not selected by perceived suitability for one of the treatment options for individual patients) OR Subgroup analysis of a randomized trial Before-after study or case series (of 10 patients) with historical controls or controls drawn from other studies Case series (of 10 patients) without controls Case reports (of <10 patients) Levels of evidence for rating studies and grading system for treatment recommendations [Carruthers 1993 ]
3 Levels of evidence for rating studies and grading system for treatment recommendations [Carruthers 1993 ]
4 March 2,2007 Courtesy of Dr Ron Falk
5
6
7
8
9
10
11
12 Treatment of MGN More than one question A who to treat B when to treat C what to target D when to stop
13 WHO 1.persistent nephrotic syndrome?if unresponsive to conservative therapy alone 2.unresponsive (remains nephrotic) despite first- line specific immunosuppression 3.impaired and/or deteriorating renal function 4.unacceptable adverse events?can this be defined
14 When 1. How long should conservative or first-line therapy be tried? 2. Is there a degree of proteinuria that should dictate initiation? 3. Are there complications of the nephrotic syndrome that should dictate starting specific therapy(when and what)? 4. Are there surrogate markers that should be used?
15 What are the options?
16 What targets should be considered a success 1. Complete or partial remission? 2. Stable GFR (+/-20%)? 3. Acceptable risk profile
17 How long (if successful) 1.Complete remission-monitor only 2.Partial remission - continue for a minimum of one year? - add an additional agent? - except this results and continue Rx indefinitely?
18 How long (if not successful) 1. No complete remission in 3-6? 2. Alternate therapy if < 50% reduction in proteinuria by 3-6? 3. More than 30% reduction in renal function regardless of improved proteinuria?
19 A RETROSPECTIVE LONGITUDINAL STUDY TO EVALUATE THE PREDICTORS OF RESPONSE TO RITUXIMAB THERAPY IN IMN PATIENTS WITH PERSISTENT NEPHROTIC PROTEINURIA Study design 14 patients: - IMN (biopsy) - Proteinuria > 3.5 g/day despite ACEi therapy Treatment: - Rituximab (4 weekly infusions, 375 mg/sqm) Main outcome: - Proteinuria Ruggenenti et al., Clin J Am Soc Nephrol, 2006
20 A RETROSPECTIVE LONGITUDINAL STUDY TO EVALUATE THE PREDICTORS OF RESPONSE TO RITUXIMAB THERAPY IN IMN PATIENTS WITH PERSISTENT NEPHROTIC PROTEINURIA Study design 14 patients: - IMN (biopsy) - Proteinuria > 3.5 g/day despite ACEi therapy Treatment: - Rituximab (4 weekly infusions, 375 mg/sqm) Main outcome: - Proteinuria LEVEL 5,Grade D Ruggenenti et al., Clin J Am Soc Nephrol, 2006
21 Decline in Renal Function in Patients Treated With Prednisone for Idiopathic Membranous Nephropathy and in Controls Level 1Grade A Cattran DC et al. N Engl J Med 1989; 320(4):
22 Level1Grade A Cameron JS et al. Q J Med 1999; 274:
23 ACTH in Patients with Membranous Nephropathy 30 nephrotic patients with idiopathic MN randomized to ACTH or no specific treatment (control) for 9 months ACTH 1.0 mg once/week alternating with 0.75 mg twice/week for the first 8 months, then 0.5 mg once/week during month 9 Complete or partial remission in 15/15 ACTH group vs. 1/15 patients in controls (p<0.0001) Results were similar after further 12-month followup Level 1 Grade A Berg A-L et al. Kidney Int 1999; 56:
24 CLINICAL STATUS AT 10 YEARS Ponticelli C et al Kidney Int 48,1600, 1995 Complete remission Partial remission Treated pts (%) P=0.020 Untreated pts (%) 7 36 Nephrotic syndrome Renal insufficiency Dialysis Death Level 1,Grade A 6 3 P=
Out of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)
Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationMembranous nephropathy. By Mohammed Kamal Nassar, MD Lecturer of Nephrology Mansoura University
Membranous nephropathy By Mohammed Kamal Nassar, MD Lecturer of Nephrology Mansoura University Membranous nephropathy Definition: Immune complex glomerular disease in which immune deposits of IgG and complement
More informationHow I Treat Membranous Nephropathy
How I Treat Membranous Nephropathy Patrick H. Nachman, MD, FASN Marion Stedman Covington Professor May 20, 2017 Treating Membranous Nephropathy: after changes upon changes we are more or less the same
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Idiopathic membranous nephropathy: use of other therapies GUIDELINES
Idiopathic membranous nephropathy: use of other therapies Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES No recommendations possible based on Level I or II evidence
More informationClinical Commissioning Policy: Rituximab for the treatment of idiopathic membranous nephropathy in adults
Clinical Commissioning Policy: Rituximab for the treatment of idiopathic membranous nephropathy in adults Reference: NHS England: 16047/P NHS England INFORMATION READER BOX Directorate Medical Operations
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Membranous nephropathy Role of alkylating agents GUIDELINES
Membranous nephropathy Role of alkylating agents Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. Treatment with alkylating agents is associated with an increased
More informationEvidence review: Rituximab for Membranous Glomerular Nephritis
NHS England Evidence review: Rituximab for Membranous Glomerular Nephritis 1 NHS England Evidence review: Rituximab for Membranous Glomerular Nephritis First published: March 2013 Updated: March 2016 Prepared
More informationMinimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong
Minimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong First, it is not uncommon Cameron JS. Am J Kidney Dis 10: 157 171,
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationDo Anti Phospholipase A2 Receptor Antibodies Predict Recurrence of Membranous Nephropathy After Transplantation?
Do Anti Phospholipase A2 Receptor Antibodies Predict Recurrence of Membranous Nephropathy After Transplantation? Rivka Ayalon MD Boston University Medical Center Idiopathic Membranous Nephropathy One of
More informationTreatment of Idiopathic Membranous Nephropathy
Treatment of Idiopathic Membranous Nephropathy Meryl Waldman and Howard A. Austin III Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health,
More informationLONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE
& LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE Senija Rašić 1 *, Amira Srna 1, Snežana Unčanin 1, Jasminka Džemidžić 1, Damir Rebić 1, Alma Muslimović 1, Maida Rakanović-Todić
More informationClots and Foamy Urine: Thrombotic Complications of Nephrotic Syndrome. Prayus Tailor, MD October 5, 2013 Renal and Hypertension Symposium
Clots and Foamy Urine: Thrombotic Complications of Nephrotic Syndrome Prayus Tailor, MD October 5, 2013 Renal and Hypertension Symposium Objectives Discuss the pathophysiology of thrombosis in nephrotic
More informationIdiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients?
O R I G N A L A R T I C L E Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? J.K.J. Deegens 1* K.J.M. Assmann 2, E.J. Steenbergen 2, L.B. Hilbrands 1, P.G.G.
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationMembranous Nephropathy and MN RADAR
Membranous Nephropathy and MN RADAR Paul Brenchley Director of Renal Research Labs Manchester Royal Infirmary RADAR Meeting Feb 28 th 2018, Birmingham Milestones in understanding Membranous Nephropathy
More informationRecurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationMembranous nephropathy: from bench to bedside
Membranous nephropathy: from bench to bedside HKSN Glomerulonephritis symposium 8 th July 2017 Peter Mathieson Bench Laboratory experiments Animal models Genetic analyses Bedside Clinical experiments Clinical
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment
Specific management of IgA nephropathy: role of triple therapy and cytotoxic therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. Triple therapy with cyclophosphamide,
More informationSteroid Resistant Nephrotic Syndrome. Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta
Steroid Resistant Nephrotic Syndrome Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta From the Departments of Nephrology, Pathology* and Biostatistics**,
More informationRussia Dialysis Society Peterhof, Russia June 8, 2016
Russia Dialysis Society Peterhof, Russia June 8, 2016 TREATMENT OF GLOMERULONEPHRITIS XV Северо-Западная ( AAV, SLE, Нефрологическая Membranous) Школа What s changed in the past decade? William Couser,
More informationTreatment Aspects of Primary Nephrotic Syndrome in Adults
& Treatment Aspects of Primary Nephrotic Syndrome in Adults Senija Rašić*¹, Snježana Unčanin¹, Jasminka Džemidžić¹, Kenana Aganović¹, Amira Srna¹, Ismar Rašić² 1. Institute for Nephrology, Clinical Centre
More informationNephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba
Nephrotic syndrome minimal change disease vs. IgA nephropathy Hadar Meringer Internal medicine B Sheba The Case 29 year old man diagnosed with nephrotic syndrome 2 weeks ago and complaining now about Lt.flank
More informationAdministration of low-dose cyclosporine alone for the treatment of elderly patients with membranous nephropathy
Administration of low-dose cyclosporine alone for the treatment of elderly patients with membranous nephropathy M.X. Li, Y.W. Yu, Z.Y. Zhang, H.D. Zhao and F.L. Xiao Department of Nephrology, The Navy
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationIgA-Nephropathy: an update on treatment Jürgen Floege
IgA-Nephropathy: an update on treatment Jürgen Floege Division of Nephrology & Immunology juergen.floege@rwth-aachen.de Floege & Feehally, Nat Rev Nephrol 2013 Floege & Eitner, J Am Soc Nephrol. 2011 If
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationPrimary Glomerulonephritides
Primary Glomerulonephritides Idiopathic Nephrotic Syndrome in Adults Stephen M. Korbet, M.D. Rush University Medical Center Chicago, Illinois 40% 35% 30% 34% 35% 33% 33% Korbet Haas 25% 20% 15% 10% 5%
More informationIdiopathic membranous nephropathy: Definition and relevance of a partial remission
Kidney International, Vol. 66 (2004), pp. 1199 1205 Idiopathic membranous nephropathy: Definition and relevance of a partial remission STÉPHAN TROYANOV, CATHERINE A. WALL, JUDITH A. MILLER, JAMES W. SCHOLEY,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of tonsillectomy GUIDELINES
Specific management of IgA nephropathy: role of tonsillectomy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES No recommendation possible based on Level I or II
More informationSo why have CKD stages I and II at all?!
So why have CKD stages I and II at all?! Structural / genetic abnormalities e.g. APKD Significant proteinuria Nephrotic range Microscopic haematoproteinuria in the absence of infection e.g. vasculitis?!!
More informationIdiopathic membranous nephropathy (IMN) is the most
A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy Vivekanand Jha,* Anirban Ganguli,* Tarun K. Saha,* Harbir S.
More informationRituximab Treatment for Membranous Nephropathy: A French Clinical and Serological Retrospective Study of 28 Patients
Original Paper This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs.0 License (www.karger.com/oa-license), applicable to the online version
More informationActhar Gel. H. P. Acthar Gel (corticotropin; ACTH) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Acthar Gel Page: 1 of 5 Last Review Date: September 18, 2015 Acthar Gel Description H. P. Acthar
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationResearch Article Transplant Outcomes in Patients with Idiopathic Membranous Nephropathy
International Nephrology Volume 2013, Article ID 818537, 4 pages http://dx.doi.org/10.1155/2013/818537 Research Article Transplant Outcomes in Patients with Idiopathic Membranous Nephropathy Claire Kennedy,
More informationDiabetes and renal disease: who does what?
CLINICAL PRACTICE Clinical Medicine 2013, Vol 13, No 5: 460 4 Diabetes and renal disease: who does what? Ruth K Jones, David Hampton, Daniel J O Sullivan and Aled O Phillips ABSTRACT Care of patients with
More informationCorporate Presentation January 2013
NASDAQ: ANTH Corporate Presentation January 2013 1 Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationResistant Nephrotic Syndrome: Review of Trials Using ACTH and a Case Series of Six Patients Treated with ACTHar
British Journal of Medicine & Medical Research 5(11): 1453-1457, 2015, Article no.bjmmr.2015.164 ISSN: 2231-0614 SCIENCEDOMAIN international www.sciencedomain.org Resistant Nephrotic Syndrome: Review of
More informationClinicopathological profile and prognosis of idiopathic membranous nephropathy in adults: a developing country perspective
ORIGINAL ARTICLE Port J Nephrol Hypert 2016; 30(2): 127-133 Advance Access publication 24 April 2016 Clinicopathological profile and prognosis of idiopathic membranous nephropathy in adults: Syed Abbas
More informationPrimary glomerulonephritides
Primary glomerulonephritides Ivan Rychlík 3rd Faculty of Medicine Charles University, Prague, Czech Republic 1 Contents of the lecture definition of GN classification clinical presentation and epidemiology
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationAtypical IgA Nephropathy
Atypical IgA Nephropathy Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA XXXIII Chilean Congress of Nephrology, Hypertension and Transplantation Puerto Varas, Chile October 6, 2016 IgA
More informationSecondary IgA Nephropathy & HSP
Secondary IgA Nephropathy & HSP Anjali Gupta, MD 1/11/11 AKI sec to Hematuria? 65 cases of ARF after an episode of macroscopic hematuria have been reported in the literature in patients with GN. The main
More informationUrinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy
NDT Advance Access published April 10, 2008 Nephrol Dial Transplant (2008) 1 of 6 doi: 10.1093/ndt/gfn190 Original Article Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy
More informationRenal Remission Clinic Protocols
Renal Remission Clinic Protocols Bremerton WA, USA Version 1.2 Issued November 5, 2009 Update January 11, 2011* *Updated items appear in red Please Read This First The protocols represent ever changing
More informationRaised serum creatinine at presentation does not adversely affect steroid response in primary focal segmental glomerulosclerosis in adults
1101 Nephrol Dial Transplant (2012) 27: 1101 1106 doi: 10.1093/ndt/gfr430 Advance Access publication 29 July 2011 Raised serum creatinine at presentation does not adversely affect steroid response in primary
More informationLow-Density Lipoprotein Apheresis Therapy for Steroid- and Cyclosporine-Resistant Idiopathic Membranous Nephropathy
CASE REPORT Low-Density Lipoprotein Apheresis Therapy for Steroid- and Cyclosporine-Resistant Idiopathic Membranous Nephropathy Yoshinori Sato,3, Shinichiro Tsunoda 2,3, Tsuyoshi Nozue 3,QinyaPan 3, Harue
More informationTacrolimus monotherapy in membranous nephropathy: A randomized controlled trial
original article http://www.kidney-international.org & 7 International Society of Nephrology see commentary on page 841 Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial M
More informationRestrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort
Q J Med 2004; 97:353 360 doi:10.1093/qjmed/hch059 Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort P.W.G.
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. HIV and the Kidney. Leah Haseley, MD. Presentation prepared by: LH NW AETC ECHO June 2012
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and the Kidney Leah Haseley, MD Presentation prepared by: LH NW AETC ECHO June 2012 Etiology of renal disease in HIV 1985- The virus 1995- The antivirals
More informationKDIGO Controversies Conference on Glomerular Diseases
KDIGO Controversies Conference on Glomerular Diseases November 16-19, 2017 Singapore Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve the care
More informationC1q nephropathy the Diverse Disease
C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining
More informationIdiopathic Membranous Nephropathy: Diagnosis and Treatment
Clinical Conference Idiopathic Membranous Nephropathy: Diagnosis and Treatment Fernando C. Fervenza,* Sanjeev Sethi, and Ulrich Specks *Division of Nephrology and Hypertension, Department of Pathology,
More informationCHAPTER 2. Primary Glomerulonephritis
2nd Report of the PRIMARY GLOMERULONEPHRITIS CHAPTER 2 Primary Glomerulonephritis Sunita Bavanandan Lee Han Wei Lim Soo Kun 21 PRIMARY GLOMERULONEPHRITIS 2nd Report of the 2.1 Introduction This chapter
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationMEMBRANOUS NEPHROPATHY: Treatment in the Modern Era
MEMBRANOUS NEPHROPATHY: Treatment in the Modern Era Richard Glassock, MD, MACP Geffen School of Medicine at UCLA KDIGO- Mumbai Nephrology Summit Mumbai, India February 6-9, 2014 QUESTION #1A A 71 year
More informationManagement of Nephrotic Syndrome
Management of Nephrotic Syndrome Treatment Strategies and Current Therapeutic Options Brad H. Rovin MD, FASN Professor of Medicine and Pathology Director, Division of Nephrology 1 DISCLOSURE STATEMENTS
More informationSCLERODERMA RENAL CRISIS. Presented by : Nouf Alanazi
SCLERODERMA RENAL CRISIS Presented by : Nouf Alanazi Agenda Prevalence Risk factors Pathology Diagnosis Prevention & monitoring Treatment Outcome & mortality. Summary & recommendations References SRC Abrupt
More informationThe nephrotic syndrome defined as urinary protein
Original Article Comparative Study of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker in the Treatment of Steroid-Resistant Idiopathic Nephrotic Syndrome NS Kumar*, AK Singh*, RN Mishra**,
More informationKDIGO GN Guideline update Evidence summary. Steroid-sensitive nephrotic syndrome. Corticosteroid therapy for nephrotic syndrome in children
KDIGO GN Guideline update Evidence summary Steroid-sensitive nephrotic syndrome Corticosteroid therapy for nephrotic syndrome in children PICO question In children (aged 3 to 18 years of age) with steroid-sensitive
More informationStepwise Treatment Using Corticosteroids Alone and in Combination with Cyclosporine in Korean Patients with Idiopathic Membranous Nephropathy
Original Article http://dx.doi.org/1.3349/ymj.213.54.4.973 pissn: 513-5796, eissn: 1976-2437 Yonsei Med J 54(4):973-982, 213 Stepwise Treatment Using Corticosteroids Alone and in Combination with Cyclosporine
More informationFactors affecting the long-term outcomes of idiopathic membranous nephropathy
Huh et al. BMC Nephrology (2017) 18:104 DOI 10.1186/s12882-017-0525-6 RESEARCH ARTICLE Factors affecting the long-term outcomes of idiopathic membranous nephropathy Hyuk Huh 1, Hajeong Lee 1, Jung Pyo
More informationGlomerulonephritis: Evidence Based Management
CHAPTER 11 Glomerulonephritis: Evidence Based Management R. A. Annigeri Introduction Glomerulonephritis is the second most common cause of end-stage renal disease (ESRD) worldwide, next only to diabetic
More informationFocal Segmental Glomerulosclerosis and the Nephro6c Syndrome Dr. A. Gangji Dr. P. Marge>s. Part 1: Clinical
Focal Segmental Glomerulosclerosis and the Nephro6c Syndrome Dr. A. Gangji Dr. P. Marge>s Part 1: Clinical Pa#ent DM 18 year old McMaster student Back pain, severe fa#gue Oct 2006 Leg swelling to ER Nov
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationreported, these are perhaps surprisingly rare given the role immunogenetics is now Table 1. Secondary membranous nephropathy (MN).
CME RENAL MEDICINE Clinical Medicine 2012, Vol 12, No 5: 461 6 CME Renal medicine Edited by Simon C Satchell, consultant senior lecturer in renal medicine, Richard Bright Renal Unit, Southmead Hospital
More informationIdiopathic membranous nephropathy (IMGN) remains the
Management of Membranous Nephropathy: When and What for Treatment Daniel Cattran Toronto General Research Institute, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada J Am Soc
More informationMembranous glomerulonephropathy (MGN) is the
CJASN epress. Published on May 28, 2009 as doi: 10.2215/CJN.06041108 Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent Patients Alfons Segarra,* Manuel
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationCurrent treatment recommendations in children with IgA nephropathy Selçuk Yüksel
Current treatment recommendations in children with IgA nephropathy Selçuk Yüksel Department of Pediatric Nephrology Pamukkale University School of Medicine IgA Nephropathy The most common cause of primary
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationREFERRAL GUIDELINES: RENAL MEDICINE
Outpatient Page 1 1 REFERRAL GUIDELINES: RENAL MEDICINE Demographic Clinical Date of birth Reason for referral Contact details (including mobile phone) Duration of symptoms Essential Referring GP details
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationChapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org chapter 6 & 2012 KDIGO Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, 181 185; doi:10.1038/kisup.2012.19
More informationDepletion of B Lymphocytes in Idiopathic Membranous Glomerulopathy: Results from Patients with Extended Follow-Up
Original Paper 1664 5529/13/0031 0001$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationSteroid-dependent nephrotic syndrome in children. Alexey Tsygin, MD, PhD NCZD Moscow, Russia
Steroid-dependent nephrotic syndrome in children Alexey Tsygin, MD, PhD NCZD Moscow, Russia Definition Nephrotic syndrome (NS) urinary albumin loss at the level of 3,5 g/1,73 m 2 /24h or 40 mg/м 2 /hour
More informationDialysis outcomes: can we do better?
Dialysis outcomes: can we do better? Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director, Chronic Disease Research Group Minneapolis Medical Research Foundation Director,
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationProf. Rosanna Coppo Director of the Nephrology, Dialysis and Transplantation Department Regina Margherita Hospital Turin, Italy. Slide 1.
ROLE OF PATHOLOGY AND CLINICAL FEATURES IN PREDICTING PROGRESSION OF IGA NEPHROPATHY: RESULTS FROM THE ERA-EDTA RESEARCH VALIGA Rosanna Coppo, Turin, Italy Chairs: François Berthoux, Saint-Etienne, France
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationNephrotic Syndrome -membranous nephropathy-
Nephrotic Syndrome -membranous nephropathy- APSN Continuing Medical Education (CME) course July 2 nd, 2014 Yokohama, Japan Shoichi Maruyama, M.D. Nagoya University Graduate School of Medicine This presentation
More informationPRIMARY GLOMERULAR DISEASES
University of Sydney PRIMARY GLOMERULAR DISEASES David Harris 8/2015 Westmead Hospital KDIGO GUIDELINES Steroid-sensitive & resistant nephrotic syndrome in children Minimal-change disease and FSGS in children
More informationClinicopathologic Characteristics of IgA Nephropathy with Steroid-responsive Nephrotic Syndrome
J Korean Med Sci 2009; 24 (Suppl 1): S44-9 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.S1.S44 Copyright The Korean Academy of Medical Sciences Clinicopathologic Characteristics of IgA Nephropathy with Steroid-responsive
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationUse of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome
Pediatr Nephrol (2003) 18:833 837 DOI 10.1007/s00467-003-1175-4 BRIEF REPORT Gina-Marie Barletta William E. Smoyer Timothy E. Bunchman Joseph T. Flynn David B. Kershaw Use of mycophenolate mofetil in steroid-dependent
More informationActhar Gel. H. P. Acthar Gel (corticotropin; ACTH) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.10 Subject: Acthar Gel Page: 1 of 6 Last Review Date: December 8, 2017 Acthar Gel Description H. P.
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationMulti-Drug Therapy Followed By Rituximab in Children with Refractory Nephrotic Syndrome Contributors
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 01 Ver. I (January. 2018), PP 05-09 www.iosrjournals.org Multi-Drug Therapy Followed By Rituximab
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationLow-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety
Renal Failure ISSN: 0886-022X (Print) 1525-6049 (Online) Journal homepage: http://www.tandfonline.com/loi/irnf20 Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness
More informationOriginal Article. Verônica Verleine Hörbe Antunes, Francisco José Veríssimo Veronese and José Vanildo Morales. Introduction
Nephrol Dial Transplant (2008) 23: 2242 2246 doi: 10.1093/ndt/gfm949 Advance Access publication 15 February 2008 Original Article Diagnostic accuracy of the protein/creatinine ratio in urine samples to
More information